Random pearls from BEST Flashcards
Pharmacologic changes re MTD in pregnancy (4)
Increased gut transit time (increased absorption), 50% increase in blood volume (lower concentration), induction in CYP3A4 activity, Increase in accumulation in adipose (supposedly can be problematic in postpartum state)
“Seeking Safety”
evidence-based treatment approach for PTSD and SUD
Network therapy def
individual psychotherapy or family therapy in which an attempt is made to involve not only immediate family members but also other relatives, friends, and neighbors as sources of emotional support and possible vocational opportunity.
Screening tool for unhealthy substance use in adolescents
CRAFFT (ridden in Car, use Alone, Family/Friends concerned, gotten in Trouble)
Schedule 1 meds
no currently accepted medical use and high potential for abuse. Heroin, LSD, cannabis, MDMA, methaqualone, peyote
Schedule 2 meds
High potential for abuse, can only be prescribed in triplicate. Cocaine, methamphetamine, opioids, meperidine, dexadrine, adderall, ritalin
Schedule 3 meds
can be prescribed by phone. Moderate-to-low potential for dependence. APAP w codeine, ketamine, anabolic steroids, testosterone
Schedule 4 meds
can be prescribed by phone. “Low” potential for abuse. Benzos, ambien, tramadol
Schedule 5 meds
can be prescribed by phone . Limited quantities of certain opioids like robitussin with codeine, lomotil, lyrica
Limbic system (hippocampus and amygdala) role in addiction
memory and emotional context (triggers)
Orbito-frontal cortex role in addiction
reward processing
Nucleus accumbens role in addiction
dopaminergic / pleasure from drugs and behaviors
Insula role in addiction
integrating and giving meaning to sensations such as hot/cold as well as cravings
Pseudowithdrawal def
intensification of symptoms when wd is imminent
Rebound def
intensification of pre-treatment symptoms after discontinuation. Distinguish from “recurrence” by whether symptoms merely returned vs intensified
Sensitization def
opposite of tolerance (increased effect with repeat doses)
“stacking” in anabolic steroids
using multiple types simultaneously
“pyramid” in anabolic steroids
increasing dose, then tapering prior to competition
Effects of anabolic steroids
increase muscle strength, but not bone mass, aerobic capacity, injury time. Can increase irritability.
In women, masculinization, weight gain, irr periods
Toxicity of anabolic steroids
PO administration associated with LFT abnormalities
anabolic steroid withdrawal illness script
Looks like depression
Gambling disorder risk and meds
DSM-5 recognized, about 50% of risk attributable to genetic influences. Meds with evidence: naltrexone, lithium, paroxetine
rate of SUD in Eds
50% of patients with eating disorder have SUDs
Gene with variants that modulate naltrexone efficacy for AUD
OPRM1
Kratom pharmacology
mitragynine. Antagonist at kappa opioid receptor, agonist vs partial agonist at mu receptor.
Salvia pharmacology and effects
salvinorin A. kappa opioid agonist→ hallucinosis and dissociation, not reliably euphoria
methanol poisoning illness script
vision loss, hyperventilation, abd pain, parksinonian features, AGMA, increased ICP. Can occur with huffing.
Tx: fomepizole.
Stages of changes and their associated pitfalls for patients
Pre-contemplative → resistance
Contemplation → demoralization
Action → dropout
Maintenance → relapse
mechanism of LSD and psilocybin
serotonin 5HT-2A agonists
Features of therapeutic community
Structured daily regimen
Assigned role models
Use of peer community as healing agent (“community-as-method”)
Active metabolites of heroin
6-MAM
morphine
3-MAM
risk of SUD attributable to genetic factors
40-60% (supposedly)
Outweighs parental substance use in adoption studies
Principles of twelve-step facilitation
Abstinence (goal)
Acceptance (of one’s loss of control over substance consumption)
Spirituality (“power greater than oneself”)
Pragmatism (collaborative approach to do whatever is needed to avoid first drink)
Role of recovery coach
Encourage healthy structures and rituals. Best utilized as part of comprehensive treatment plan
Unique toxicity of meperidine
Decreased seizure threshold d/t normeperidine accumulation
PNPLA3 and MBOAT7
genes associated with incr risk of alcohol-related liver disease
GABRA2
gene likely associated with severity of AWS and daily alcohol use